Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | PDE4A | P27815 | 1/20 | 0.49 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.49 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.49 |
| ▸ | TNF | P01375 | 9/20 | 0.46 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12937753 | 0.88 | BRD4 (0.67) | BRD4ALDH1A1KDM4EKMT2APDE4A | |
| SCHEMBL4460099 | 0.86 | BRD4 (0.64) | BRD4ALDH1A1KDM4EKMT2APDE4A | |
| SCHEMBL4447367 | 0.86 | BRD4 (0.64) | BRD4ALDH1A1KDM4EKMT2APDE4A | |
| SCHEMBL4460421 | 0.81 | BRD4 (0.58) | BRD4ALDH1A1KMT2APDE4APDE4B | |
| SCHEMBL3081962 | 0.81 | KMT2A (0.42) | BRD4ALDH1A1KDM4EKMT2AGAA | |
| SCHEMBL9322233 | 0.79 | KMT2A (0.47) | ALDH1A1KDM4EKMT2AGAA | |
| SCHEMBL4458626 | 0.79 | BRD4 (0.58) | BRD4ALDH1A1PDE4APDE4BPDE4C | |
| SCHEMBL24650410 | 0.78 | PDE4B (0.53) | BRD4ALDH1A1KDM4EKMT2APDE4A | |
| SCHEMBL22815609 | 0.78 | BRD4 (0.82) | BRD4ALDH1A1GAA | |
| SCHEMBL3970718 | 0.78 | KMT2A (0.44) | ALDH1A1KDM4EKMT2APDE4AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580822-B2 | Compositions, synthesis, and methods of using indanone based cholinesterase inhibitors | REVIVA PHARMACEUTICALS, INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-8580822-B2 | Compositions, synthesis, and methods of using indanone based cholinesterase inhibitors | REVIVA PHARMACEUTICALS, INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-20120252842-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING INDANONE BASED CHOLINESTERASE INHIBITORS | REVIVA PHARMACEUTICALS, INC. (US) | 2012-10-04 | — | — | US | disclosed |
| US-20120252842-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING INDANONE BASED CHOLINESTERASE INHIBITORS | REVIVA PHARMACEUTICALS, INC. (US) | 2012-10-04 | — | — | US | disclosed |
| US-8247563-B2 | 5,6-dimethoxy-2-(piperidin-4-ylmethyl)-2,3-dihydro-1H-inden-1-one ; for therapy of Alzheimer's disease, myasthenia gravis, Huntingtons disease or glaucoma | REVIVA PHARMACEUTICALS, INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-8247563-B2 | 5,6-dimethoxy-2-(piperidin-4-ylmethyl)-2,3-dihydro-1H-inden-1-one ; for therapy of Alzheimer's disease, myasthenia gravis, Huntingtons disease or glaucoma | REVIVA PHARMACEUTICALS, INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-8247563-B2 | 5,6-dimethoxy-2-(piperidin-4-ylmethyl)-2,3-dihydro-1H-inden-1-one ; for therapy of Alzheimer's disease, myasthenia gravis, Huntingtons disease or glaucoma | REVIVA PHARMACEUTICALS, INC. (US) | 2012-08-21 | — | — | US | disclosed |
| EP-2114166-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING INDANONE BASED CHOLINESTERASE INHIBITORS | Reviva Pharmaceuticals, Inc. (US) | 2009-11-11 | — | — | EP | disclosed |
| US-20080153878-A1 | Compositions, synthesis, and methods of using indanone based cholinesterase inhibitors | REVIVA PHARMACEUTICALS, INC. (US) | 2008-06-26 | — | — | US | disclosed |
| US-20080153878-A1 | Compositions, synthesis, and methods of using indanone based cholinesterase inhibitors | REVIVA PHARMACEUTICALS, INC. (US) | 2008-06-26 | — | — | US | disclosed |
| US-20080153878-A1 | Compositions, synthesis, and methods of using indanone based cholinesterase inhibitors | REVIVA PHARMACEUTICALS, INC. (US) | 2008-06-26 | — | — | US | disclosed |
| WO-2008073452-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING INDANONE BASED CHOLINESTERASE INHIBITORS | REVIVA PHARMACEUTICALS, INC. (US) | 2008-06-19 | — | — | WO | disclosed |
| WO-2008073452-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING INDANONE BASED CHOLINESTERASE INHIBITORS | REVIVA PHARMACEUTICALS, INC. (US) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153878-A1 | Compositions, synthesis, and methods of using indanone based cholinesterase inhibitors | ACHE, BCHE, CHKA | BRD4 1094/4885ALDH1A1 595/4885KDM4E 447/4885 |
| US-20120252842-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING INDANONE BASED CHOLINESTERASE INHIBITORS | ACHE, BCHE, CHKA | BRD4 1094/4885ALDH1A1 595/4885KDM4E 447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.